FDA Inspection
Hemarus LLCHemarus LLC – FDA Inspection, Apr 30, 2024
Record Details
This FDA Inspection record concerns Hemarus LLC, with an inspection on April 30, 2024, issued by the Center for Biologics Evaluation and Research, covering biologics.
View Company Profile
ID · 77674ace-ff97-4ad1-80bd-769e8481a0e7
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1234618
- FDA center
- Biologics
- Project area
- Blood and Blood Products
FDA Citations
12- 21 CFR 630.5(c)(1)Improper delegation of activities - SP & plasmapheresis
- 21 CFR 606.20(b)Qualifications of responsible personnel
- 21 CFR 606.171Biological product deviation report
- 21 CFR 606.100(b)Establish, maintain and follow manufacturing SOPs
- 21 CFR 606.40(a)(1)Provide space for examination
- 21 CFR 606.121(c)(2)Name, address, unique facility identifier
- 21 CFR 606.160(a)(2)Determination of lot numbers and supplies
- 21 CFR 606.170(a)Adverse Reaction - Investigations
- 21 CFR 630.15(b)(2)Responsible physician not on site
- 21 CFR 606.160(d)Retention period
Showing 10 of 12 citations.
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Hemarus LLC
2| Date | Classification | Office | Project area |
|---|---|---|---|
| June 18, 2026 | Not classified | Florida District Office | |
| November 4, 2022 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for Hemarus LLC
- FDA Inspection 1323742 - 2026-06-18
- FDA Inspection 1187347 - 2022-11-04
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.